Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study
Open Access
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 59, 229-231
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
This publication has 4 references indexed in Scilit:
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- Pre-Defined Subgroups Analyses of TOWER, a Placebo-Controlled Phase 3 Trial of Teriflunomide in Patients with Relapsing Multiple Sclerosis (S41.006)Neurology, 2013
- Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisMultiple Sclerosis Journal, 2012
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple SclerosisNew England Journal of Medicine, 2011